Kardium’s device is called the Globe System – a 122 gold electrode catheter that delivers pulsed field energy to the heart. Image credit: Business Wire/Kardium.

Kardium has completed enrolment in a study evaluating its pulsed-field ablation (PFA) device for the treatment of atrial fibrillation.

According to a ClinicalTrials.gov entry, the PULSAR trial (NCT05462145) is estimated to enrol 449 participants with the heart condition.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Kardium’s device is called the Globe System – a 122 gold electrode catheter that delivers pulsed field energy to the heart. Pulsed-field ablation is an emerging promising technology that uses electric field energy to destroy diseased heart tissue while keeping neighbouring structures intact. Traditional methods frequently use thermal energy, which can sometimes damage local tissue.

Canada-based Kardium says its catheter electrodes can map the patient’s cardiac anatomy and electrical activity. The energy can be precisely targeted to the area of interest, according to the study’s co-principal investigator, Dr Atul Verma.

The PULSAR study, operating under an investigational device exemption (IDE) by the US Food and Drug Administration (FDA), will assess efficacy in patients a year after a treatment procedure with the Globe system. Primary outcomes will include the number of subjects with freedom from documented atrial fibrillation, atrial flutter, and atrial tachycardia. Safety will be measured within a week of the procedure.

Data from the study will be used to support a pre-market approval (PMA) application to the FDA.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Kardium’s CEO Kevin Chaplin said: “We are committed to working closely with the FDA during the PMA submission process to bring this state-of-the-art technology to the market.”

Medtronic received FDA approval for its PulseSelect system to become the first pulsed-field ablation catheter approved in the US in December 2023. Boston Scientific gained US approval for its Farapulse system earlier this year. Both Medtronic’s PulseSelect and Biosense Webster’s are also approved in Europe to treat atrial fibrillation.

A report by GlobalData estimates the global ablation catheter market will grow to $3.8bn in 2033, up from $2.5bn in 2023. The market model places Biosense Webster, Abbott and Medtronic as market leaders.